Soreness After Deep Dry Needling of One Latent Myofascial Trigger Point

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

Pain after dry needling or injection in the muscle is a frequent secondary effect in the treatment of myofascial pain syndrome. In this trial pain and sensitivity will be assessed during a 72 hours follow up period. Factors that may contribute to higher levels of pain or sensitivity will be evaluated.

See also
	Status	Clinical Trial	Phase
	Completed	`NCT01608633` - Effects of Spray and Stretch on Postneedling Soreness and Sensitivity After Dry Needling of a Latent Myofascial Trigger Point.	Phase 2

NCT number	NCT02158104
Study type	Observational
Source	CEU San Pablo University
Contact
Status	Completed
Phase	Phase 2/Phase 3
Start date	October 2013

Soreness After Deep Dry Needling of One Latent Myofascial Trigger Point

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms